Media Articles Related to Tofranil-PM (Imipramine)
List Depression as Heart Disease Risk Factor, AHA Panel Says
Source: theheart.org | Medscape Cardiology Headlines [2014.02.28]
Depression should join the ranks of obesity, diabetes, hypertension, and smoking as an official heart disease risk factor, an expert AHA panel says.
Medscape Medical News
Music as therapeutic intervention can relieve anxiety and depression in older people
Source: Complementary Medicine / Alternative Medicine News From Medical News Today [2014.02.27]
Using music and singing in health care can improve quality of life for older people by easing pain, anxiety and depression.According to an article published in Mental Health Practice, the practices can be easily and effectively used as therapeutic nursing interventions.
Depression a risk for heart disease
Source: Depression News From Medical News Today [2014.02.26]
An extensive review of scientific literature indicates that depression should be added to the list of risk factors associated with heart disease. Others include obesity, diabetes, high blood pressure and smoking.A 12-person panel of experts that included Robert M. Carney, PhD, and Kenneth E. Freedland, PhD, both professors of psychiatry at Washington University School of Medicine in St.
Augmenting SSRIs in Treatment-Resistant Depression
Source: Medscape Psychiatry & Mental Health Headlines [2014.02.25]
A review considers the question of which of 2 agents provides the most benefit, and best value, when single-agent therapy of depression is insufficient.
Thyroid activity within normal range tied to depression in older adults
Source: Depression News From Medical News Today [2014.02.24]
When older individuals' thyroid glands are more active than average, it may be a risk factor for depression, according to new research accepted for publication in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).Beyond its role in regulating the body's metabolism, the thyroid gland also can influence mental health.
Published Studies Related to Tofranil-PM (Imipramine)
Comparison between imipramine and imipramine combined with pseudoephedrine in 5-12-year-old children with uncomplicated enuresis: a double-blind clinical trial. [2011.02]
OBJECTIVE: Monosymptomatic nocturnal enuresis is a common entity, with a prevalence of 10% at the age of 7 years. For its primary treatment, we compared the effect of combination medical therapy (imipramine with pseudoephedrine) with imipramine alone... CONCLUSION: The additive pharmacologic effects of imipramine with pseudoephedrine for the treatment of monosymptomatic nocturnal enuresis in children were well tolerated, and gave significantly faster results than single drug therapy using imipramine. The moderate-to-high recurrence rate following discontinuation of medical treatment indicates the need for a longer term study involving more cases. Crown Copyright (c) 2010. Published by Elsevier Ltd. All rights reserved.
Comparison between imipramine and imipramine combined with pseudoephedrine in
5-12-year-old children with uncomplicated enuresis: a double-blind clinical
imipramine alone... CONCLUSION: The additive pharmacologic effects of imipramine with pseudoephedrine
Serum zinc level in depressed patients during zinc supplementation of imipramine treatment. [2010.11]
BACKGROUND: Recurrent major depression is associated with decreased blood zinc concentrations that may be increased by effective antidepressant therapy. Some clinical investigations point to alterations of the zinc level in blood as a potential marker of depression... CONCLUSIONS: Serum zinc is a state marker of depression. Copyright (c) 2010 Elsevier B.V. All rights reserved.
Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. [2010.06]
PURPOSE: Painful neuropathic conditions of cancer pain often show little response to nonopioid and opioid analgesics but may be eased by antidepressants and anticonvulsants. Although gabapentin is effective in the treatment of neuropathic pain in patients with cancer, some patients experience intolerable side effects sufficient to warrant discontinuation. The aim of this study was to see whether low-dose gabapentin is effective in treating cancer-related neuropathic pain when combined with low-dose imipramine... CONCLUSION: Low-dose gabapentin-antidepressant combination with opioids was effective in managing neuropathic cancer pain without severe adverse effects.
Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. [2010.03]
CONCLUSION: That unipolar psychotic depression should be treated with a combination of an antidepressant and an antipsychotic and not with an antidepressant alone, can be considered evidence based with regard to venlafaxine-quetiapine vs. venlafaxine monotherapy. Whether this is also the case for imipramine monotherapy is likely, but cannot be concluded from the data.
Clinical Trials Related to Tofranil-PM (Imipramine)
Imipramine and Pregabalin Combination in Painful Polyneuropathy [Not yet recruiting]
Polyneuropathy of different etiologies is often associated with pain and the standard
treatment for this type of pain is gabapentinoids or antidepressants. The hypothesis of this
study is that the combination of the gabapentinoid pregabalin and the antidepressant
imipramine will provide better pain relief than the single compounds alone.
This is a randomized, placebo-controlled, double-blind, 4-way, cross-over trial of
pregabalin 300 mg/day, imipramine 75 mg/day and their combination versus placebo. The study
will include 60 patients and the treatment outcome will be pain intensity as measured by
numeric rating scales.
Imipramine Treatment for Patients With Multi-organ Bodily Distress Syndrome [Recruiting]
The aim of this study is to test the effect of the tricyclic antidepressant Imipramine in
patients with longlasting health problems with no known medical explanation, defined as
multi-organ Bodily distress syndrome (BDS). Pharmacological treatment of patients with BDS
have never been tested, and Imipramine i low dosage (10-75 mg) has the potential of reducing
both pain and other symptoms of bodily distress for patients with BDS. Control conditions
are pill placebo. Study duration is 19 weeks for each of the 140 patients.
The Efficacy of Imipramine in Treatment of Functional Dyspepsia [Recruiting]
The aim of this study is evaluate the efficacy of Imipramine, a tricyclic antidepressant, in
treatment of functional dyspepsia. This is a double blind randomised placebo controlled
trial in which consecutive patients with diagnosis of functional dyspepsia will be studied.
After exclusion of organic cause of dyspepsia by endoscopy, these patients will be randomly
assigned to either imipramine or placebo. All the patients will enter an additional 4 weeks
of drug withdrawal phase after the initial 12 weeks of study drug treatment. They will be
evaluated for treatment response, which is defined as satisfactory relief of dyspeptic
symptoms at the end of 12-week treatment.
Efficacy of Imipramine for Treatment of Patients With Esophageal Hypersensitivity/ Functional Heartburn [Recruiting]
Esophageal hypersensitivity/Functional heartburn are common among non-erosive reflux disease
(NERD) patients who do not response to proton pump inhibitors. Whether tricyclic
antidepressant improves NERD patient's symptoms remains unknown
Aim of this randomized controlled trial study is to determine the efficacy of imipramine,
which could increase esophageal pain thresholds in healthy volunteers, in comparison with
placebo for treatment patients with esophageal hypersensitivity or functional heartburn
evaluated by improvement of specific-symptom score and quality of life
Linking Altered Central Pain Processing and Genetic Polymorphism to Drug Efficacy in Chronic Low Back Pain (Predictio) [Recruiting]
Drug therapy in patients with chronic low back pain is a major challenge for physicians. One
of the problems is the lacking knowledge in prediction of drug efficacy in a chosen patient.
Usually one of the classes of pain medication is given to patients with a similar clinical
picture, although different pain mechanisms may be responsible for this clinical picture.
Another reason for variable drug efficacy are genetic polymorphisms, this may be the reason
why an unique drug produces different responses (from a lacking analgesic effect up to
excessive effect or side-effects.
Quantitative sensory testing is a method that documents alterations in the pain perception
system. Linking genetic polymorphisms to quantitative sensory testing may give us a tool for
anticipation of drug efficacy.